Aclaris Therapeutics IncACRS
Price$5.26Intrinsic value$3.6431% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $8.2M-56.1% YoYTTM through 30 Jun 2026
Net Income -$75.7MTTM through 30 Jun 2026
Free Cash Flow -$62.2MTTM through 30 Jun 2026

Margins

Current
Gross Margin80.2%
Operating Margin-1,111.8%
Net Margin-921.5%

Returns

-48.5%ROE
-35.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.97x
Net Debt-$190.8Mnet cash position
Cash & Equivalents$19.2M

Quality Metrics

Altman Z-Score0.23
Piotroski F-Score2 / 9
FCF Margin-756.5%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $7.8M
Diluted EPS-$0.58TTM
'19'20'21'22'23'24'25
FY2025: $-0.53

Dividend

No dividend

Capital Allocation

Capex Intensity1.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.